Ulcerative colitis and Crohn's disease are the principal forms of inflammatory bowel disease.
Both represent chronic inflammation of the gastrointestinal tract, which displays …

Background & Aims We compared the efficacy and safety of different first-line (biologic-
naïve) and second-line (prior exposure to tumor necrosis factor [TNF] antagonists) agents for …

Ulcerative colitis (UC) is an idiopathic inflammatory disorder. These guidelines indicate the
preferred approach to the management of adults with UC and represent the official practice …

Background & Aims We performed a systematic review and meta-analysis to evaluate the
comparative risk of serious infections with tumor necrosis factor (TNF) antagonists, non-TNF …

Background There are limited data to inform positioning of agents for treating moderate‐
severe ulcerative colitis (UC). Aim To assess comparative efficacy and safety of different …

A subset of patients with ulcerative colitis (UC) present with, or progress to, moderate to
severe disease activity. These patients are at high risk for colectomy, hospitalization …

Background & Aims Current knowledge regarding the epidemiology of pouchitis is based on
highly selected, mostly single-center, patient cohorts. Our objective was to prospectively …

Background & Aims Pouchitis is the most common complication after ileal pouch-anal
anastomosis (IPAA) for ulcerative colitis (UC); however, clinical and environmental risk …

Abstract Purpose of Review Biologics for the treatment of inflammatory bowel disease (IBD)
have been transformative to the therapeutic goals in the pediatric population. We review the …

The availability of biologic therapies in inflammatory bowel disease (IBD) is increasing
significantly. This represents more options to treat patients, but also more difficulties in …